TSP49091-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures after exposure to valrubicin


TSA213660-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin


TSA213702-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin


TSA213750-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin


TSA213804-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin


TSA213858-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin


TSA213907-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin


TSA213960-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin


TSA214012-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin


TSA214042-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin


TSA214093-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin


TSA214123-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin


TSA214173-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin


TSA214226-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin


TSA217724-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HUVEC.A after exposure to valrubicin


TSF504938-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 1.11 µM for 24.0 h


1 subfactor(s)
TSF504939-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.37 µM for 24.0 h


1 subfactor(s)
TSF504936-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 10.0 µM for 24.0 h


1 subfactor(s)
TSF504937-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 3.33 µM for 24.0 h


1 subfactor(s)
TSF504940-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.125 µM for 24.0 h


1 subfactor(s)
TSF504941-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.04 µM for 24.0 h


1 subfactor(s)
TSF611377-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 2.22 µM for 24.0 h


1 subfactor(s)
TSF611378-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.74 µM for 24.0 h


1 subfactor(s)
TSF611379-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.25 µM for 24.0 h


1 subfactor(s)
TSF611380-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.08 µM for 24.0 h


1 subfactor(s)
TSF611381-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.03 µM for 24.0 h


1 subfactor(s)
TSF611382-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.01 µM for 24.0 h


1 subfactor(s)
TSF505225-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 10.0 µM for 24.0 h


1 subfactor(s)
TSF505226-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 3.33 µM for 24.0 h


1 subfactor(s)
TSF505227-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 1.11 µM for 24.0 h


1 subfactor(s)
TSF505228-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.37 µM for 24.0 h


1 subfactor(s)
TSF505229-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.125 µM for 24.0 h


1 subfactor(s)
TSF505230-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.04 µM for 24.0 h


1 subfactor(s)
TSF611712-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 2.22 µM for 24.0 h


1 subfactor(s)
TSF611713-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.74 µM for 24.0 h


1 subfactor(s)
TSF611714-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.25 µM for 24.0 h


1 subfactor(s)
TSF611715-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.08 µM for 24.0 h


1 subfactor(s)
TSF611716-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.03 µM for 24.0 h


1 subfactor(s)
TSF611717-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.01 µM for 24.0 h


1 subfactor(s)
TSF505529-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 10.0 µM for 24.0 h


1 subfactor(s)
TSF505530-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 3.33 µM for 24.0 h


1 subfactor(s)
TSF505531-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 1.11 µM for 24.0 h


1 subfactor(s)
TSF505532-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.37 µM for 24.0 h


1 subfactor(s)
TSF505533-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.125 µM for 24.0 h


1 subfactor(s)
TSF505534-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.04 µM for 24.0 h


1 subfactor(s)
TSF612049-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.25 µM for 24.0 h


1 subfactor(s)
TSF612047-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 2.22 µM for 24.0 h


1 subfactor(s)
TSF612052-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.01 µM for 24.0 h


1 subfactor(s)
TSF612048-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.74 µM for 24.0 h


1 subfactor(s)
TSF612050-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.08 µM for 24.0 h


1 subfactor(s)
TSF612051-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.03 µM for 24.0 h


1 subfactor(s)
TSF505855-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 10.0 µM for 24.0 h


1 subfactor(s)
TSF505858-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.37 µM for 24.0 h


1 subfactor(s)
TSF505856-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 3.33 µM for 24.0 h


1 subfactor(s)
TSF505857-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 1.11 µM for 24.0 h


1 subfactor(s)
TSF505859-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.125 µM for 24.0 h


1 subfactor(s)
TSF505860-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.04 µM for 24.0 h


1 subfactor(s)
TSF612382-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 2.22 µM for 24.0 h


1 subfactor(s)
TSF612385-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.08 µM for 24.0 h


1 subfactor(s)
TSF612383-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.74 µM for 24.0 h


1 subfactor(s)
TSF612384-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.25 µM for 24.0 h


1 subfactor(s)
TSF612386-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.03 µM for 24.0 h


1 subfactor(s)
TSF612387-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.01 µM for 24.0 h


1 subfactor(s)
TSF506183-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 1.11 µM for 24.0 h


1 subfactor(s)
TSF506181-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 10.0 µM for 24.0 h


1 subfactor(s)
TSF506182-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 3.33 µM for 24.0 h


1 subfactor(s)
TSF506184-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.37 µM for 24.0 h


1 subfactor(s)
TSF506185-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.125 µM for 24.0 h


1 subfactor(s)
TSF506186-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.04 µM for 24.0 h


1 subfactor(s)
TSF612717-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.74 µM for 24.0 h


1 subfactor(s)
TSF612716-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 2.22 µM for 24.0 h


1 subfactor(s)
TSF612718-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.25 µM for 24.0 h


1 subfactor(s)
TSF612719-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.08 µM for 24.0 h


1 subfactor(s)
TSF612720-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.03 µM for 24.0 h


1 subfactor(s)
TSF612721-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.01 µM for 24.0 h


1 subfactor(s)
TSF506486-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 10.0 µM for 24.0 h


1 subfactor(s)
TSF506487-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 3.33 µM for 24.0 h


1 subfactor(s)
TSF506488-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 1.11 µM for 24.0 h


1 subfactor(s)
TSF506489-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.37 µM for 24.0 h


1 subfactor(s)
TSF506490-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.125 µM for 24.0 h


1 subfactor(s)
TSF506491-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.04 µM for 24.0 h


1 subfactor(s)
TSF613051-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 2.22 µM for 24.0 h


1 subfactor(s)
TSF613054-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.08 µM for 24.0 h


1 subfactor(s)
TSF613052-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.74 µM for 24.0 h


1 subfactor(s)
TSF613053-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.25 µM for 24.0 h


1 subfactor(s)
TSF613055-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.03 µM for 24.0 h


1 subfactor(s)
TSF613056-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.01 µM for 24.0 h


1 subfactor(s)
TSF506810-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 10.0 µM for 24.0 h


1 subfactor(s)
TSF506811-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 3.33 µM for 24.0 h


1 subfactor(s)
TSF506814-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.125 µM for 24.0 h


1 subfactor(s)
TSF506812-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 1.11 µM for 24.0 h


1 subfactor(s)
TSF506813-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.37 µM for 24.0 h


1 subfactor(s)
TSF506815-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.04 µM for 24.0 h


1 subfactor(s)
TSF613722-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 2.22 µM for 24.0 h


1 subfactor(s)
TSF613723-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.74 µM for 24.0 h


1 subfactor(s)
TSF613724-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.25 µM for 24.0 h


1 subfactor(s)
TSF613725-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.08 µM for 24.0 h


1 subfactor(s)
TSF613726-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.03 µM for 24.0 h


1 subfactor(s)
TSF613727-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.01 µM for 24.0 h


1 subfactor(s)
TSF507131-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 10.0 µM for 24.0 h


1 subfactor(s)
TSF507132-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 3.33 µM for 24.0 h


1 subfactor(s)
TSF507133-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 1.11 µM for 24.0 h


1 subfactor(s)
TSF507134-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.37 µM for 24.0 h


1 subfactor(s)
TSF507135-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.125 µM for 24.0 h


1 subfactor(s)
TSF507136-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.04 µM for 24.0 h


1 subfactor(s)
TSF614057-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 2.22 µM for 24.0 h


1 subfactor(s)
TSF614058-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.74 µM for 24.0 h


1 subfactor(s)
TSF614059-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.25 µM for 24.0 h


1 subfactor(s)
TSF614060-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.08 µM for 24.0 h


1 subfactor(s)
TSF614061-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.03 µM for 24.0 h


1 subfactor(s)
TSF614062-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.01 µM for 24.0 h


1 subfactor(s)
TSF507419-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 10.0 µM for 24.0 h


1 subfactor(s)
TSF507420-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 3.33 µM for 24.0 h


1 subfactor(s)
TSF507421-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 1.11 µM for 24.0 h


1 subfactor(s)
TSF507422-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.37 µM for 24.0 h


1 subfactor(s)
TSF507423-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.125 µM for 24.0 h


1 subfactor(s)
TSF507424-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.04 µM for 24.0 h


1 subfactor(s)
TSF614389-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.74 µM for 24.0 h


1 subfactor(s)
TSF614388-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 2.22 µM for 24.0 h


1 subfactor(s)
TSF614390-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.25 µM for 24.0 h


1 subfactor(s)
TSF614391-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.08 µM for 24.0 h


1 subfactor(s)
TSF614392-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.03 µM for 24.0 h


1 subfactor(s)
TSF614393-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.01 µM for 24.0 h


1 subfactor(s)
TSF507742-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 10.0 µM for 24.0 h


1 subfactor(s)
TSF507743-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 3.33 µM for 24.0 h


1 subfactor(s)
TSF507744-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 1.11 µM for 24.0 h


1 subfactor(s)
TSF507745-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.37 µM for 24.0 h


1 subfactor(s)
TSF507746-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.125 µM for 24.0 h


1 subfactor(s)
TSF507747-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.04 µM for 24.0 h


1 subfactor(s)
TSF614721-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.74 µM for 24.0 h


1 subfactor(s)
TSF614720-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 2.22 µM for 24.0 h


1 subfactor(s)
TSF614723-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.08 µM for 24.0 h


1 subfactor(s)
TSF614722-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.25 µM for 24.0 h


1 subfactor(s)
TSF614724-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.03 µM for 24.0 h


1 subfactor(s)
TSF614725-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.01 µM for 24.0 h


1 subfactor(s)
TSF508003-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 10.0 µM for 24.0 h


1 subfactor(s)
TSF508004-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 3.33 µM for 24.0 h


1 subfactor(s)
TSF508005-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 1.11 µM for 24.0 h


1 subfactor(s)
TSF508006-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.37 µM for 24.0 h


1 subfactor(s)
TSF508007-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.125 µM for 24.0 h


1 subfactor(s)
TSF508008-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.04 µM for 24.0 h


1 subfactor(s)
TSF615055-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 2.22 µM for 24.0 h


1 subfactor(s)
TSF615058-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.08 µM for 24.0 h


1 subfactor(s)
TSF615056-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.74 µM for 24.0 h


1 subfactor(s)
TSF615057-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.25 µM for 24.0 h


1 subfactor(s)
TSF615060-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.01 µM for 24.0 h


1 subfactor(s)
TSF615059-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.03 µM for 24.0 h


1 subfactor(s)
TSF508323-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 1.11 µM for 24.0 h


1 subfactor(s)
TSF508324-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.37 µM for 24.0 h


1 subfactor(s)
TSF508321-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 10.0 µM for 24.0 h


1 subfactor(s)
TSF508322-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 3.33 µM for 24.0 h


1 subfactor(s)
TSF508325-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.125 µM for 24.0 h


1 subfactor(s)
TSF508326-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.04 µM for 24.0 h


1 subfactor(s)
TSF615389-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.25 µM for 24.0 h


1 subfactor(s)
TSF615387-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 2.22 µM for 24.0 h


1 subfactor(s)
TSF615388-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.74 µM for 24.0 h


1 subfactor(s)
TSF615392-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.01 µM for 24.0 h


1 subfactor(s)
TSF615390-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.08 µM for 24.0 h


1 subfactor(s)
TSF615391-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.03 µM for 24.0 h


1 subfactor(s)
TSF508646-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 3.33 µM for 24.0 h


1 subfactor(s)
TSF508645-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 10.0 µM for 24.0 h


1 subfactor(s)
TSF508649-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.125 µM for 24.0 h


1 subfactor(s)
TSF508647-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 1.11 µM for 24.0 h


1 subfactor(s)
TSF508648-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.37 µM for 24.0 h


1 subfactor(s)
TSF508650-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.04 µM for 24.0 h


1 subfactor(s)
TSF615720-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 2.22 µM for 24.0 h


1 subfactor(s)
TSF615721-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.74 µM for 24.0 h


1 subfactor(s)
TSF615724-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.03 µM for 24.0 h


1 subfactor(s)
TSF615722-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.25 µM for 24.0 h


1 subfactor(s)
TSF615723-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.08 µM for 24.0 h


1 subfactor(s)
TSF615725-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.01 µM for 24.0 h


1 subfactor(s)
TSF613387-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HUVEC.A after exposure to valrubicin 2.22 µM for 24.0 h


1 subfactor(s)
TSF613388-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HUVEC.A after exposure to valrubicin 0.74 µM for 24.0 h


1 subfactor(s)
TSF613389-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HUVEC.A after exposure to valrubicin 0.25 µM for 24.0 h


1 subfactor(s)
TSF613390-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HUVEC.A after exposure to valrubicin 0.08 µM for 24.0 h


1 subfactor(s)
TSF613391-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HUVEC.A after exposure to valrubicin 0.03 µM for 24.0 h


1 subfactor(s)
TSF613392-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HUVEC.A after exposure to valrubicin 0.01 µM for 24.0 h


1 subfactor(s)
TSS504948-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 1.11 µM for 24.0 h


TSS504949-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.37 µM for 24.0 h


TSS504946-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 10.0 µM for 24.0 h


TSS504947-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 3.33 µM for 24.0 h


TSS504950-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.125 µM for 24.0 h


TSS504951-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.04 µM for 24.0 h


TSS611388-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 2.22 µM for 24.0 h


TSS611389-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.74 µM for 24.0 h


TSS611390-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.25 µM for 24.0 h


TSS611391-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.08 µM for 24.0 h


TSS611392-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.03 µM for 24.0 h


TSS611393-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to valrubicin 0.01 µM for 24.0 h


TSS505235-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 10.0 µM for 24.0 h


TSS505236-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 3.33 µM for 24.0 h


TSS505237-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 1.11 µM for 24.0 h


TSS505238-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.37 µM for 24.0 h


TSS505239-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.125 µM for 24.0 h


TSS505240-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.04 µM for 24.0 h


TSS611723-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 2.22 µM for 24.0 h


TSS611724-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.74 µM for 24.0 h


TSS611725-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.25 µM for 24.0 h


TSS611726-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.08 µM for 24.0 h


TSS611727-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.03 µM for 24.0 h


TSS611728-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to valrubicin 0.01 µM for 24.0 h


TSS505539-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 10.0 µM for 24.0 h


TSS505540-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 3.33 µM for 24.0 h


TSS505541-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 1.11 µM for 24.0 h


TSS505542-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.37 µM for 24.0 h


TSS505543-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.125 µM for 24.0 h


TSS505544-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.04 µM for 24.0 h


TSS612060-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.25 µM for 24.0 h


TSS612058-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 2.22 µM for 24.0 h


TSS612063-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.01 µM for 24.0 h


TSS612059-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.74 µM for 24.0 h


TSS612061-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.08 µM for 24.0 h


TSS612062-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to valrubicin 0.03 µM for 24.0 h


TSS505865-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 10.0 µM for 24.0 h


TSS505868-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.37 µM for 24.0 h


TSS505866-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 3.33 µM for 24.0 h


TSS505867-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 1.11 µM for 24.0 h


TSS505869-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.125 µM for 24.0 h


TSS505870-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.04 µM for 24.0 h


TSS612393-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 2.22 µM for 24.0 h


TSS612396-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.08 µM for 24.0 h


TSS612394-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.74 µM for 24.0 h


TSS612395-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.25 µM for 24.0 h


TSS612397-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.03 µM for 24.0 h


TSS612398-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to valrubicin 0.01 µM for 24.0 h


TSS506193-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 1.11 µM for 24.0 h


TSS506191-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 10.0 µM for 24.0 h


TSS506192-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 3.33 µM for 24.0 h


TSS506194-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.37 µM for 24.0 h


TSS506195-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.125 µM for 24.0 h


TSS506196-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.04 µM for 24.0 h


TSS612728-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.74 µM for 24.0 h


TSS612727-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 2.22 µM for 24.0 h


TSS612729-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.25 µM for 24.0 h


TSS612730-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.08 µM for 24.0 h


TSS612731-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.03 µM for 24.0 h


TSS612732-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to valrubicin 0.01 µM for 24.0 h


TSS506496-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 10.0 µM for 24.0 h


TSS506497-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 3.33 µM for 24.0 h


TSS506498-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 1.11 µM for 24.0 h


TSS506499-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.37 µM for 24.0 h


TSS506500-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.125 µM for 24.0 h


TSS506501-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.04 µM for 24.0 h


TSS613062-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 2.22 µM for 24.0 h


TSS613065-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.08 µM for 24.0 h


TSS613063-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.74 µM for 24.0 h


TSS613064-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.25 µM for 24.0 h


TSS613066-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.03 µM for 24.0 h


TSS613067-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to valrubicin 0.01 µM for 24.0 h


TSS506820-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 10.0 µM for 24.0 h


TSS506821-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 3.33 µM for 24.0 h


TSS506824-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.125 µM for 24.0 h


TSS506822-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 1.11 µM for 24.0 h


TSS506823-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.37 µM for 24.0 h


TSS506825-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.04 µM for 24.0 h


TSS613733-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 2.22 µM for 24.0 h


TSS613734-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.74 µM for 24.0 h


TSS613735-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.25 µM for 24.0 h


TSS613736-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.08 µM for 24.0 h


TSS613737-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.03 µM for 24.0 h


TSS613738-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to valrubicin 0.01 µM for 24.0 h


TSS507141-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 10.0 µM for 24.0 h


TSS507142-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 3.33 µM for 24.0 h


TSS507143-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 1.11 µM for 24.0 h


TSS507144-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.37 µM for 24.0 h


TSS507145-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.125 µM for 24.0 h


TSS507146-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.04 µM for 24.0 h


TSS614068-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 2.22 µM for 24.0 h


TSS614069-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.74 µM for 24.0 h


TSS614070-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.25 µM for 24.0 h


TSS614071-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.08 µM for 24.0 h


TSS614072-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.03 µM for 24.0 h


TSS614073-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to valrubicin 0.01 µM for 24.0 h


TSS507429-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 10.0 µM for 24.0 h


TSS507430-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 3.33 µM for 24.0 h


TSS507431-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 1.11 µM for 24.0 h


TSS507432-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.37 µM for 24.0 h


TSS507433-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.125 µM for 24.0 h


TSS507434-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.04 µM for 24.0 h


TSS614400-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.74 µM for 24.0 h


TSS614399-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 2.22 µM for 24.0 h


TSS614401-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.25 µM for 24.0 h


TSS614402-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.08 µM for 24.0 h


TSS614403-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.03 µM for 24.0 h


TSS614404-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to valrubicin 0.01 µM for 24.0 h


TSS507752-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 10.0 µM for 24.0 h


TSS507753-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 3.33 µM for 24.0 h


TSS507754-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 1.11 µM for 24.0 h


TSS507755-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.37 µM for 24.0 h


TSS507756-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.125 µM for 24.0 h


TSS507757-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.04 µM for 24.0 h


TSS614732-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.74 µM for 24.0 h


TSS614731-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 2.22 µM for 24.0 h


TSS614734-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.08 µM for 24.0 h


TSS614733-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.25 µM for 24.0 h


TSS614735-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.03 µM for 24.0 h


TSS614736-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to valrubicin 0.01 µM for 24.0 h


TSS508013-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 10.0 µM for 24.0 h


TSS508014-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 3.33 µM for 24.0 h


TSS508015-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 1.11 µM for 24.0 h


TSS508016-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.37 µM for 24.0 h


TSS508017-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.125 µM for 24.0 h


TSS508018-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.04 µM for 24.0 h


TSS615066-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 2.22 µM for 24.0 h


TSS615069-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.08 µM for 24.0 h


TSS615067-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.74 µM for 24.0 h


TSS615068-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.25 µM for 24.0 h


TSS615071-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.01 µM for 24.0 h


TSS615070-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to valrubicin 0.03 µM for 24.0 h


TSS508333-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 1.11 µM for 24.0 h


TSS508334-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.37 µM for 24.0 h


TSS508331-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 10.0 µM for 24.0 h


TSS508332-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 3.33 µM for 24.0 h


TSS508335-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.125 µM for 24.0 h


TSS508336-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.04 µM for 24.0 h


TSS615400-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.25 µM for 24.0 h


TSS615398-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 2.22 µM for 24.0 h


TSS615399-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.74 µM for 24.0 h


TSS615403-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.01 µM for 24.0 h


TSS615401-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.08 µM for 24.0 h


TSS615402-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to valrubicin 0.03 µM for 24.0 h


TSS508656-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 3.33 µM for 24.0 h


TSS508655-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 10.0 µM for 24.0 h


TSS508659-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.125 µM for 24.0 h


TSS508657-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 1.11 µM for 24.0 h


TSS508658-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.37 µM for 24.0 h


TSS508660-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.04 µM for 24.0 h


TSS615731-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 2.22 µM for 24.0 h


TSS615732-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.74 µM for 24.0 h


TSS615735-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.03 µM for 24.0 h


TSS615733-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.25 µM for 24.0 h


TSS615734-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.08 µM for 24.0 h


TSS615736-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to valrubicin 0.01 µM for 24.0 h


TSS613398-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HUVEC.A after exposure to valrubicin 2.22 µM for 24.0 h


TSS613399-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HUVEC.A after exposure to valrubicin 0.74 µM for 24.0 h


TSS613400-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HUVEC.A after exposure to valrubicin 0.25 µM for 24.0 h


TSS613401-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HUVEC.A after exposure to valrubicin 0.08 µM for 24.0 h


TSS613402-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HUVEC.A after exposure to valrubicin 0.03 µM for 24.0 h


TSS613403-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HUVEC.A after exposure to valrubicin 0.01 µM for 24.0 h



TSP49091 - CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures after exposure to valrubicin Public

https://clue.io/data/CMap2020#LINCS2020

Experimental design

No experimental design provided

Results

No results provided